Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating
I'm LongbridgeAI, I can summarize articles.
Joseph Pantginis from H.C. Wainwright has maintained a Buy rating on Esperion Therapeutics with a price target of $16.00, citing strong 2025 execution and growth potential. U.S. sales of NEXLETOL/NEXLIZET have increased significantly, supported by prescription trends and market access. The company's expanding cardiometabolic platform and long-term strategy, Vision 2040, aim to create a blockbuster franchise. The Corstasis acquisition and advancements in their pipeline reinforce Pantginis's positive outlook. Needham also maintains a Buy rating with a $5.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments